---

---

AGENDA

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT

In this symposium, FDA will provide an overview of CDER experience with approving several solid oral drug products which benefited from the continuous manufacturing technologies. We will also provide case-studies of intramural and extramural research in the areas of nanomaterials and continuous manufacturing, to further encourage the innovation and adoption of continuous manufacturing. Lastly, we will discuss ways in which industry, academia and other regulatory agencies can collaborate and engage with FDA in advancing the field of nanotechnology and continuous manufacturing.

INTENDED AUDIENCE

• Regulatory science and regulatory affairs professionals working on IND/NDA/BLA/ANDA etc.
• Researchers working on nanomaterials, drug delivery system, gene delivery systems, liposomes, lipid nanoparticles, biologics or continuous manufacturing
• Consultants focused on early- and late- stage product development and manufacturing
• Foreign regulators

TOPICS COVERED

• CDER experience in approving solid oral drug products utilizing continuous manufacturing
• FDA extramural research on various types of continuous manufacturing technologies for liposomes and lipid nanoparticles
• FDA intramural research on characterization of drug products containing nanomaterials
• Regulatory considerations on nanomaterial drug products
• Ways to engage with FDA on regulatory science research

FDA RESOURCES

• Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry.
• Q13 Continuous Manufacturing of Drug Substances and Drug Products.
• FDA Emerging Technology Program.
• Adam F et al. An audit of pharmaceutical continuous manufacturing regulatory submissions and outcomes in the US. International Journal of Pharmaceutics, (2022), 622, 121778.